Imaging Study in Metastatic Clear Cell RCC.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby, które ukończyły 18 lat.
- •Pacjenci z potwierdzonym rakiem nerkowokomórkowym z przerzutami, którego obecność potwierdzono w badaniu histologicznym (np. biopsji).
✗ Disqualifies
- •Osoby przyjmujące pewne leki (wymienione w opisie badania), których nie można odstawić na czas przed podaniem środka do badań.
- •Kobiety w ciąży lub karmiące piersią.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
Research Facility
Saint Leonards, Australia
Research Facility
Nedlands, Australia
Research Facility
Perth, Australia
Research Facility
Christchurch, New Zealand
Trial contact
RayzeBio Clinical Trials
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/30/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.